Livzon Pharmaceutical Group Inc. (HKG:1513)

Market Cap	30.37B +4.0%
Revenue (ttm)	13.31B -0.3%
Net Income	2.23B -6.1%
EPS	2.51 -3.9%
Shares Out	n/a
PE Ratio	13.61
Forward PE	12.84
Dividend	1.20 (4.29%)
Ex-Dividend Date	Jun 13, 2025

Volume	466,970
Average Volume	879,791
Open	27.92
Previous Close	27.92
Day's Range	27.46 - 28.06
52-Week Range	25.90 - 41.85
Beta	0.28
RSI	43.65
Earnings Date	Apr 23, 2026

About HKG:1513

Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People’s Republic of China and internationally. The company offers leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for the assisted reproduction field; Ilaprazole enteric-coated tablets, ilaprazole sodium for injection, and bismuth potassium citrate products for the gastrointestinal field; fluvoxamine maleate for the psychiatric and neuro...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1985
• Employees: 8,878
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1513

Financial Performance

In 2025, HKG:1513's revenue was 12.02 billion, an increase of 1.76% compared to the previous year's 11.81 billion. Earnings were 2.02 billion, a decrease of -1.84%.

Financial numbers in CNY